Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

 

Post-ASCO 2024 GI Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Dr Elizabeth Smyth | Moderator: Dr Samuel Klempner & Professor Florian Lordick
24 June | 12:00–14:00 CDT/ 18:00–20:00 BST/ 19:00–21:00 CEST


Draft Agenda

(subject to change)

Timings are in CDT

12:00–12:10 | Session 1: Optimizing surgical approaches in CRC
  • Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial – #LBA3501: Martijn Meijerink
  • Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer – #LBA3502: Elske Gootjes
12:10–12:25 | Panel discussion
12:25–12:45 | Session 2: Advances in systemic approaches in CRC
  • Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET) – #3500: Rene Adam
  • NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer – #LBA3504: Kai-Keen Shiu
  • A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy – #LBA500: Pierfranco Conte
  • Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study –#3505TBC
12:45–13:00 | Panel discussion
13:00–13:15 | Session 3: Latest chemotherapy approaches in gastroesophageal and pancreatic cancers
  • A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186 – #4003: Efrat Dotan
  • Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01 – #LBA4004: Jennifer Knox
  • Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial) – #LBA1: Jens Höppner
13:15–13:30 | Panel discussion
13:30–13:45 | Session 4: Novel combination approaches in gastroesophageal and hepatobiliary cancers
  • Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial – #LBA4001: Salah-Eddin Al-Batran
  • Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: the ARMANI phase III trial – #LBA4002: Filippo Pietrantonio
  • Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW – #LBA4008: Peter Robert Galle
13:45–14:00 | Panel discussion
14:00 | End of webinar


This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.